Early Probiotic Supplementation of Healthy Term Infants with <i>Bifidobacterium longum</i> subsp. <i>infantis</i> M-63 Is Safe and Leads to the Development of <i>Bifidobacterium</i>-Predominant Gut Microbiota: A Double-Blind, Placebo-Controlled Trial
Bifidobacteria are important intestinal bacteria that provide a variety of health benefits in infants. We investigated the efficacy and safety of <i>Bifidobacterium longum</i> subsp. <i>infantis</i> (<i>B. infantis</i>) M-63 in healthy infants in a double-blind, r...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Nutrients |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6643/15/6/1402 |
| _version_ | 1797609693083860992 |
|---|---|
| author | Akari Hiraku Setsuko Nakata Mai Murata Chendong Xu Natsumi Mutoh Satoshi Arai Toshitaka Odamaki Noriyuki Iwabuchi Miyuki Tanaka Takahisa Tsuno Masahiko Nakamura |
| author_facet | Akari Hiraku Setsuko Nakata Mai Murata Chendong Xu Natsumi Mutoh Satoshi Arai Toshitaka Odamaki Noriyuki Iwabuchi Miyuki Tanaka Takahisa Tsuno Masahiko Nakamura |
| author_sort | Akari Hiraku |
| collection | DOAJ |
| description | Bifidobacteria are important intestinal bacteria that provide a variety of health benefits in infants. We investigated the efficacy and safety of <i>Bifidobacterium longum</i> subsp. <i>infantis</i> (<i>B. infantis</i>) M-63 in healthy infants in a double-blind, randomized, placebo-controlled trial. Healthy term infants were given <i>B. infantis</i> M-63 (n = 56; 1 × 10<sup>9</sup> CFU/day) or placebo (n = 54) from postnatal age ≤ 7 days to 3 months. Fecal samples were collected, and fecal microbiota, stool pH, short-chain fatty acids, and immune substances were analyzed. Supplementation with <i>B. infantis</i> M-63 significantly increased the relative abundance of <i>Bifidobacterium</i> compared with the placebo group, with a positive correlation with the frequency of breastfeeding. Supplementation with <i>B. infantis</i> M-63 led to decreased stool pH and increased levels of acetic acid and IgA in the stool at 1 month of age compared with the placebo group. There was a decreased frequency of defecation and watery stools in the probiotic group. No adverse events related to test foods were observed. These results indicate that early supplementation with <i>B. infantis</i> M-63 is well tolerated and contributes to the development of <i>Bifidobacterium</i>-predominant gut microbiota during a critical developmental phase in term infants. |
| first_indexed | 2024-03-11T06:04:19Z |
| format | Article |
| id | doaj.art-9104c9c5bde444109372de29896129cd |
| institution | Directory Open Access Journal |
| issn | 2072-6643 |
| language | English |
| last_indexed | 2024-03-11T06:04:19Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Nutrients |
| spelling | doaj.art-9104c9c5bde444109372de29896129cd2023-11-17T13:05:16ZengMDPI AGNutrients2072-66432023-03-01156140210.3390/nu15061402Early Probiotic Supplementation of Healthy Term Infants with <i>Bifidobacterium longum</i> subsp. <i>infantis</i> M-63 Is Safe and Leads to the Development of <i>Bifidobacterium</i>-Predominant Gut Microbiota: A Double-Blind, Placebo-Controlled TrialAkari Hiraku0Setsuko Nakata1Mai Murata2Chendong Xu3Natsumi Mutoh4Satoshi Arai5Toshitaka Odamaki6Noriyuki Iwabuchi7Miyuki Tanaka8Takahisa Tsuno9Masahiko Nakamura10Food Ingredients and Technology Institute, R & D Division, Morinaga Milk Industry Co., Ltd., 5-1-83, Higashihara, Zama 252-8583, JapanDepartment of Pediatrics, Matsumoto City Hospital, 4417-180, Hata, Matsumoto 390-1401, JapanFood Ingredients and Technology Institute, R & D Division, Morinaga Milk Industry Co., Ltd., 5-1-83, Higashihara, Zama 252-8583, JapanFood Ingredients and Technology Institute, R & D Division, Morinaga Milk Industry Co., Ltd., 5-1-83, Higashihara, Zama 252-8583, JapanFood Ingredients and Technology Institute, R & D Division, Morinaga Milk Industry Co., Ltd., 5-1-83, Higashihara, Zama 252-8583, JapanFood Ingredients and Technology Institute, R & D Division, Morinaga Milk Industry Co., Ltd., 5-1-83, Higashihara, Zama 252-8583, JapanNext Generation Science Institute, R & D Division, Morinaga Milk Industry Co., Ltd., 5-1-83, Higashihara, Zama 252-8583, JapanFood Ingredients and Technology Institute, R & D Division, Morinaga Milk Industry Co., Ltd., 5-1-83, Higashihara, Zama 252-8583, JapanFood Ingredients and Technology Institute, R & D Division, Morinaga Milk Industry Co., Ltd., 5-1-83, Higashihara, Zama 252-8583, JapanDepartment of Pediatrics, Matsumoto City Hospital, 4417-180, Hata, Matsumoto 390-1401, JapanDepartment of neurosurgery, Matsumoto City Hospital, 4417-180, Hata, Matsumoto 390-1401, JapanBifidobacteria are important intestinal bacteria that provide a variety of health benefits in infants. We investigated the efficacy and safety of <i>Bifidobacterium longum</i> subsp. <i>infantis</i> (<i>B. infantis</i>) M-63 in healthy infants in a double-blind, randomized, placebo-controlled trial. Healthy term infants were given <i>B. infantis</i> M-63 (n = 56; 1 × 10<sup>9</sup> CFU/day) or placebo (n = 54) from postnatal age ≤ 7 days to 3 months. Fecal samples were collected, and fecal microbiota, stool pH, short-chain fatty acids, and immune substances were analyzed. Supplementation with <i>B. infantis</i> M-63 significantly increased the relative abundance of <i>Bifidobacterium</i> compared with the placebo group, with a positive correlation with the frequency of breastfeeding. Supplementation with <i>B. infantis</i> M-63 led to decreased stool pH and increased levels of acetic acid and IgA in the stool at 1 month of age compared with the placebo group. There was a decreased frequency of defecation and watery stools in the probiotic group. No adverse events related to test foods were observed. These results indicate that early supplementation with <i>B. infantis</i> M-63 is well tolerated and contributes to the development of <i>Bifidobacterium</i>-predominant gut microbiota during a critical developmental phase in term infants.https://www.mdpi.com/2072-6643/15/6/1402term infantgut microbiotaprobiotics<i>Bifidobacterium longum</i> subsp. <i>Infantis</i>GI motilityshort-chain fatty acids |
| spellingShingle | Akari Hiraku Setsuko Nakata Mai Murata Chendong Xu Natsumi Mutoh Satoshi Arai Toshitaka Odamaki Noriyuki Iwabuchi Miyuki Tanaka Takahisa Tsuno Masahiko Nakamura Early Probiotic Supplementation of Healthy Term Infants with <i>Bifidobacterium longum</i> subsp. <i>infantis</i> M-63 Is Safe and Leads to the Development of <i>Bifidobacterium</i>-Predominant Gut Microbiota: A Double-Blind, Placebo-Controlled Trial Nutrients term infant gut microbiota probiotics <i>Bifidobacterium longum</i> subsp. <i>Infantis</i> GI motility short-chain fatty acids |
| title | Early Probiotic Supplementation of Healthy Term Infants with <i>Bifidobacterium longum</i> subsp. <i>infantis</i> M-63 Is Safe and Leads to the Development of <i>Bifidobacterium</i>-Predominant Gut Microbiota: A Double-Blind, Placebo-Controlled Trial |
| title_full | Early Probiotic Supplementation of Healthy Term Infants with <i>Bifidobacterium longum</i> subsp. <i>infantis</i> M-63 Is Safe and Leads to the Development of <i>Bifidobacterium</i>-Predominant Gut Microbiota: A Double-Blind, Placebo-Controlled Trial |
| title_fullStr | Early Probiotic Supplementation of Healthy Term Infants with <i>Bifidobacterium longum</i> subsp. <i>infantis</i> M-63 Is Safe and Leads to the Development of <i>Bifidobacterium</i>-Predominant Gut Microbiota: A Double-Blind, Placebo-Controlled Trial |
| title_full_unstemmed | Early Probiotic Supplementation of Healthy Term Infants with <i>Bifidobacterium longum</i> subsp. <i>infantis</i> M-63 Is Safe and Leads to the Development of <i>Bifidobacterium</i>-Predominant Gut Microbiota: A Double-Blind, Placebo-Controlled Trial |
| title_short | Early Probiotic Supplementation of Healthy Term Infants with <i>Bifidobacterium longum</i> subsp. <i>infantis</i> M-63 Is Safe and Leads to the Development of <i>Bifidobacterium</i>-Predominant Gut Microbiota: A Double-Blind, Placebo-Controlled Trial |
| title_sort | early probiotic supplementation of healthy term infants with i bifidobacterium longum i subsp i infantis i m 63 is safe and leads to the development of i bifidobacterium i predominant gut microbiota a double blind placebo controlled trial |
| topic | term infant gut microbiota probiotics <i>Bifidobacterium longum</i> subsp. <i>Infantis</i> GI motility short-chain fatty acids |
| url | https://www.mdpi.com/2072-6643/15/6/1402 |
| work_keys_str_mv | AT akarihiraku earlyprobioticsupplementationofhealthyterminfantswithibifidobacteriumlongumisubspiinfantisim63issafeandleadstothedevelopmentofibifidobacteriumipredominantgutmicrobiotaadoubleblindplacebocontrolledtrial AT setsukonakata earlyprobioticsupplementationofhealthyterminfantswithibifidobacteriumlongumisubspiinfantisim63issafeandleadstothedevelopmentofibifidobacteriumipredominantgutmicrobiotaadoubleblindplacebocontrolledtrial AT maimurata earlyprobioticsupplementationofhealthyterminfantswithibifidobacteriumlongumisubspiinfantisim63issafeandleadstothedevelopmentofibifidobacteriumipredominantgutmicrobiotaadoubleblindplacebocontrolledtrial AT chendongxu earlyprobioticsupplementationofhealthyterminfantswithibifidobacteriumlongumisubspiinfantisim63issafeandleadstothedevelopmentofibifidobacteriumipredominantgutmicrobiotaadoubleblindplacebocontrolledtrial AT natsumimutoh earlyprobioticsupplementationofhealthyterminfantswithibifidobacteriumlongumisubspiinfantisim63issafeandleadstothedevelopmentofibifidobacteriumipredominantgutmicrobiotaadoubleblindplacebocontrolledtrial AT satoshiarai earlyprobioticsupplementationofhealthyterminfantswithibifidobacteriumlongumisubspiinfantisim63issafeandleadstothedevelopmentofibifidobacteriumipredominantgutmicrobiotaadoubleblindplacebocontrolledtrial AT toshitakaodamaki earlyprobioticsupplementationofhealthyterminfantswithibifidobacteriumlongumisubspiinfantisim63issafeandleadstothedevelopmentofibifidobacteriumipredominantgutmicrobiotaadoubleblindplacebocontrolledtrial AT noriyukiiwabuchi earlyprobioticsupplementationofhealthyterminfantswithibifidobacteriumlongumisubspiinfantisim63issafeandleadstothedevelopmentofibifidobacteriumipredominantgutmicrobiotaadoubleblindplacebocontrolledtrial AT miyukitanaka earlyprobioticsupplementationofhealthyterminfantswithibifidobacteriumlongumisubspiinfantisim63issafeandleadstothedevelopmentofibifidobacteriumipredominantgutmicrobiotaadoubleblindplacebocontrolledtrial AT takahisatsuno earlyprobioticsupplementationofhealthyterminfantswithibifidobacteriumlongumisubspiinfantisim63issafeandleadstothedevelopmentofibifidobacteriumipredominantgutmicrobiotaadoubleblindplacebocontrolledtrial AT masahikonakamura earlyprobioticsupplementationofhealthyterminfantswithibifidobacteriumlongumisubspiinfantisim63issafeandleadstothedevelopmentofibifidobacteriumipredominantgutmicrobiotaadoubleblindplacebocontrolledtrial |